You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News items for the week of June 8, 2020.
As part of the distribution agreement, Biolidics will distribute the IncellDx bioINK kit with Biolidics' ClearCell FX1 system.
The flow cytometry-based assays were developed by Menlo Park, California-based IncellDx to run on Beckman Coulter instrumentation.
As part of the agreement, Kindstar will use InCellDx's single-cell immuno-oncology and oncology diagnostic products in China, including Hong Kong and Macao.
IncellDx has partnered with Ann Arbor, Michigan-based Zomedica to identify and enumerate circulating tumor cells from canine cancers using InCellDx's BioINK liquid biopsy reagent platform.
IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
The deal covers IncellDx's portfolio of immune-oncology & oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells & immune cell subtypes.
Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.
Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.
Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.
In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.